Samsung Bioepis Participates in European Renal Association Congress, Highlights Value of Rare Disease Treatment

"Striving to Build a Sustainable Healthcare System"

Samsung Bioepis is participating in the European Renal Association (ERA) Annual Congress, which is being held in Austria from June 4 to June 7.

At the European Renal Association (ERA) Annual Congress held in Austria from the 4th to the 7th. Samsung Bioepis

Continuing from last year, Samsung Bioepis has set up an on-site booth this year as well, providing an opportunity to introduce the company to global stakeholders in the field of nephrology. Through this, the company plans to promote the efficacy and value of Epysclis, its rare disease treatment currently sold in Europe.

Epysclis is a biosimilar of Soliris. Soliris is a rare disease treatment developed by Alexion Pharmaceuticals in the United States, used for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis, among other conditions.

Soliris is known as a representative ultra-high-priced biopharmaceutical with significant unmet needs in the medical field. Its global sales last year reached approximately 3.8 trillion KRW (2.588 billion USD). The annual treatment cost for major indications amounts to several hundred million KRW.

A Samsung Bioepis official stated, "Epysclis is playing an important role in expanding treatment options for patients suffering from rare diseases in the European market. Going forward, we will continue to actively explore global markets such as Europe and the United States to provide more patients with treatment opportunities and strive to build a sustainable healthcare system."

Meanwhile, Samsung Bioepis is recognized for improving patient access to ultra-high-priced medicines by launching Epysclis in the global market at a reasonable price. Since its launch in Europe in 2023, the product has achieved the number one market share among biosimilars in Germany and Italy, and has also secured contracts with the largest purchasing group in France and the state government of the Netherlands.